Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.

Clinical Presentation 1: A 68-year-old man with a history of treated dyslipidemia was admitted with non–ST-segment–elevation myocardial infarction (MI). Coronary angiography showed a thrombotic subtotal occlusion of the proximal dominant right coronary artery and 50% stenosis in the mid left anterior descending and first obtuse marginal arteries. He underwent percutaneous coronary intervention (PCI) to the proximal right coronary artery with a second-generation drug-eluting stent (DES). How do you decide on the duration of dual antiplatelet therapy (DAPT) in this individual? Clinical Presentation 2: An 81-year-old woman weighing 52 kg with a history of hypertension and gastroesophageal reflux disease presented with Canadian Cardiovascular Society class III stable angina. Myocardial perfusion imaging showed a moderate area of anterior ischemia. At coronary angiography, she had an eccentric 95% calcified lesion in the mid left anterior descending artery. She also had mild disease (≈30% stenosis) in the proximal right coronary and mid left circumflex coronary arteries. The left anterior descending artery was stented with a second-generation DES. How do you apply the evidence for DAPT in this patient? DAPT with aspirin and a P2Y12 receptor inhibitor is an essential component of the treatment of patients with acute coronary syndromes (ACS) and those undergoing PCI. DAPT after ACS reduces death and MI compared with aspirin alone, both in patients treated with PCI and in those who are managed conservatively.1–3 After elective PCI for stable coronary disease, DAPT reduces ischemic events and stent thrombosis (ST).4,5 However, these benefits come at the cost of increased risk of bleeding,6 raising the question about how to best balance efficacy and safety in determining the duration of DAPT. ### What Is the Evidence? Current treatment guidelines recommend 1 year of DAPT after ACS.7–9 This recommendation is based largely on the duration of treatment in …

[1]  Marc P. Bonaca,et al.  Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.

[2]  Seung‐Jung Park,et al.  Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. , 2015, Journal of the American College of Cardiology.

[3]  Giuseppe Biondi-Zoccai,et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.

[4]  S. Windecker,et al.  Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. , 2015, Journal of the American College of Cardiology.

[5]  Walter Desmet,et al.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.

[6]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[7]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[8]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[9]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[10]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[12]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[13]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[14]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[15]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[16]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[17]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[18]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[19]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[20]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[21]  Caroline A Milton,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt , 2001 .